- By FYH News Team
[ad_1]
Ramsay Health Care
FY22 Interim Result Presentation
6 months ended 31st December 2021
Managing Director & CEO, Craig McNally
Group Chief Financial Officer, Martyn Roberts
People caring for people.
Important Information
This presentation is in summary form and is not necessarily complete. It should be read together with the Ramsay Group’s unaudited consolidated financial statements lodged with the ASX on 24th February 2022.
This presentation contains information that is based on projected and/or estimated expectations, assumptions or outcomes. Forward looking statements are subject to a range of risk factors. Ramsay cautions against reliance on any forward-looking statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by COVID-19.
While Ramsay has prepared this information based on its current knowledge and understanding and in good faith, there are risks and uncertainties involved which could cause results to differ from projections. Ramsay will not be liable for the correctness and/or accuracy of the information, nor any differences between the information provided and actual outcomes, and reserves the right to change its projections from time to time. The Ramsay Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this presentation, subject to disclosure obligations under the applicable law and ASX listing rules.
2 Results Briefing – Six months ended 31 December 2021
Key Themes
Group Financial Highlights
Regional Highlights & Outlooks
Group Financials
Strategic Direction & Group Outlook
Questions
3 Results Briefing – Six months ended 31 December 2021
Key Themes
Ramsay’s employees, clinicians and facilities continued to support the public sector and the community response to the pandemic
Result severely impacted by new waves of COVID. When operating conditions allowed, activity levels improved
The management of employee availability in the short term combined with recruitment and retention of our people in the medium term are significant challenges facing the business
Investment in brownfield expansion and reconfiguration of existing facilities remains a focus
The business continues to build its digital and data foundations to leverage the existing business base and support entry into adjacent health services
Elysium acquisition builds on Ramsay’s strong position in mental health and acute care and delivers opportunities for organic and inorganic growth in the UK
Balance sheet remains strong, capacity for further investment
“Ramsay Cares” strategy focused on driving action through healthier people, stronger communities and a thriving planet
The business is well positioned to benefit from the additional volume created by the backlog of elective surgery and a building pipeline of non surgical cases
4 Results Briefing – Six months ended 31 December 2021
Group 1HFY22 Financial Highlights
- Earnings were materially impacted by the ongoing disruption caused by high COVID cases on activity levels, case mix and costs
- Removing the impact of non-recurring items⁵, profit before tax declined 1.3% on the pcp
- Balance sheet remains strong, post Elysium acquisition proforma⁶ funding group⁷ leverage, 2.4 x
- Fully franked interim dividend of 48.5cps was determined, flat on the pcp
|
Half year Ended 31 December A$’m |
$’m |
% chg on |
|
pcp |
||
|
Total revenue and other income (less interest income) |
6,687.4 |
1.2 |
|
EBITDAR¹ |
1,009.6 |
(8.8) |
|
EBITDA² |
952.6 |
(8.3) |
|
EBIT³ |
489.2 |
(16.2) |
|
PBT⁴ |
303.7 |
(23.8) |
|
Minority interests attributable to non-controlling interests |
(49.9) |
(26.0) |
|
Statutory Net Profit to owners |
158.9 |
(29.7) |
|
Interim dividend per share (DPS) (cps) |
48.5 |
– |
|
Fully diluted earnings per share (EPS) (cps) |
67.7 |
(30.1) |
- Earnings before interest, tax, depreciation, amortisation, and rent
- Earnings before interest, tax, depreciation and amortisation
- Earnings before interest and tax
- Profit before tax
- Non-recurringitems -$34.7m in FY22 vs $43.4m in pcp refer Review of Results from Operations
- Proforma assumes the Elysium Healthcare transaction completed on 31st January 2022 was complete on 31st December 2021
- Funding group excludes Ramsay Santé and Ramsay Sime Darby. Banking covenants calculated on this basis
5 Results Briefing – Six months ended 31 December 2021
This is an excerpt of the original content. To continue reading it, access the original document here.
Disclaimer
Ramsay Health Care Limited published this content on 24 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 February 2022 22:33:36 UTC.
Publicnow 2022
|
|
|
|
|
|
|
||||
|
||||
Technical analysis trends RAMSAY HEALTH CARE LIMITED
| Short Term | Mid-Term | Long Term | |
| Trends | Neutral | Bearish | Bearish |
Income Statement Evolution
|
Sell  Buy |
|
| Mean consensus | OUTPERFORM |
| Number of Analysts | 16 |
| Last Close Price | 64,56 AUD |
| Average target price | 72,48 AUD |
| Spread / Average Target | 12,3% |
[ad_2]
Source link
Trending Topics
Features
- Drive Toolkit
Download and distribute powerful vaccination QI resources for your community.
- Health Champions
Sign up now to support health equity and sustainable health outcomes in your community.
- Cancer Early Detection
MCED tests use a simple blood draw to screen for many kinds of cancer at once.
- PR
FYHN is a bridge connecting health information providers to BIPOC communities in a trusted environment.
- Medicare
Discover an honest look at our Medicare system.
- Alliance for Representative Clinical Trials
ARC was launched to create a network of community clinicians to diversify and bring clinical trials to communities of color and other communities that have been underrepresented.
- Reducing Patient Risk
The single most important purpose of our healthcare system is to reduce patient risk for an acute event.
- Subash Kafle
- Subash Kafle
- Jessica Wilson
